Investigational drug · Phase 3
CHO Cell
Also called: recombinant zoster vaccine, Recombinant Respiratory Syncytial Virus Vaccine, CHO cells, Recombinant Herpes Zoster Vaccine, Recombinant Zoster Vaccine SYS6052, 0 and 30 days schedule, 0 and 60 days schedule
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
7 still active
All registered trials
119
Any phase or sponsor naming "CHO Cell"
First trial start
2023
May 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CHO Cell", any sponsor or status.
Conditions studied
As listed on its trial records.
- Herpes Zoster
- Respiratory Syncytial Virus (RSV)
- Herpes Zoster (HZ)
Approved drugs for the same conditions: RSV · Herpes and shingles · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "CHO Cell" as an intervention, largest first.
- Safety Study of COVID19 Vaccine on the MarketStatus unknown
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT05890521 · 100,000 participants (planned) · Start Apr 2, 2022 · Primary completion Jun 16, 2022
Drug: Recombinant new coronavirus vaccine (CHO cell) · For: COVID-19
Sites: Changsha, China
- A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19Pivotal-lookingStatus unknown
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT04646590 · 28,904 participants · Start Dec 16, 2020 · Primary completion Nov 28, 2021
Drug: Recombinant new coronavirus vaccine (CHO cell) group; Recombinant new coronavirus vaccine (CHO cells) placebo group · For: Prevention of COVID-19; Safety and Efficacy
Sites: Changsha, China; Guayaquil, Ecuador; Quito, Ecuador · 18 sites in all
- Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and OlderPivotal-lookingActive, not recruiting
MAXVAX Biotechnology Limited Liability CompanyIndustry
NCT06447779 · 25,000 participants (planned) · Start Jul 13, 2024 · Primary completion Mar 29, 2026
Drug: Recombinant Zoster Vaccine (CHO Cell); NaCl solution Placebo · For: Herpes Zoster
Sites: Shijiazhuang, China; Zhengzhou, China; Wuhan, China · 4 sites in all
- Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)Pivotal-lookingRecruiting
MAXVAX Biotechnology Limited Liability CompanyIndustry
NCT07272434 · 25,000 participants (planned) · Start Oct 22, 2025 · Primary completion Jul 31, 2026
Drug: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell); Placebo (Saline solution) · For: Respiratory Syncytial Virus (RSV)
Sites: Guangzhou, China; Shijiazhuang, China; Zhengzhou, China · 8 sites in all
- Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Pivotal-lookingRecruiting
Beijing BeneWill Technology Development Co., LtdAcademic, hospital or other
NCT07860216 · 25,000 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 31, 2028
Drug: Recombinant respiratory syncytial virus vaccine (CHO cell); Sodium Chloride Injection 0.9% · For: Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Sites: GuiZhou, China; Hebei, China; HuBei, China · 7 sites in all
- The Phase Ⅱ/Ⅲ Trial of LYB001Pivotal-lookingStatus unknown
Yantai Patronus Biotech Co., Ltd.Industry
NCT05602558 · 18,000 participants (planned) · Start Dec 2022 · Primary completion Dec 2023
Drug: LYB001; Placebo · For: COVID-19
- Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical TrialPivotal-lookingStatus unknown
National Vaccine and Serum Institute, ChinaIndustry
NCT05599516 · 16,000 participants (planned) · Start Nov 4, 2022 · Primary completion Oct 2023
Drug: LIBP-Rec-Vaccine; BIBP-Rec-Vaccine and 1 more · For: COVID-19; Coronavirus Infections
Sites: SEHA, United Arab Emirates
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)Pivotal-lookingActive, not recruiting
MAXVAX Biotechnology Limited Liability CompanyIndustry
NCT07293065 · 12,000 participants (planned) · Start Dec 15, 2025 · Primary completion Dec 31, 2027
Drug: Recombinant Zoster Vaccine (CHO Cell); NaCl solution Placebo · For: Herpes Zoster
Sites: Shijiazhuang, China; Zhengzhou, China; Wuhan, China · 4 sites in all
- Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)Pivotal-lookingCompleted
Jiangsu Rec-Biotechnology Co., Ltd.Industry
NCT05398848 · 7,623 participants · Start Oct 31, 2022 · Primary completion Sep 4, 2023
Drug: Recombinant two-component COVID-19 vaccine (CHO cell); Placebo · For: COVID-19
Sites: Dharān, Nepal; Aramil, Russia; Izhevsk, Russia · 11 sites in all
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Plug-and-Play or Plug-and-Pray? Impact of random versus targeted integration on the linearity and orthogonality of synthetic gene circuits in CHO cells.
Lim SLY, Nielsen LK, Jiménez Del Val I, et al. · Synth Syst Biotechnol 2027
- Data-Driven Mechanistic Modeling of Untargeted Metabolome Data.
Mäkinen M, Chotteau V · Methods Mol Biol 2027
- Late-stage large extracellular vesicles reprogram CHO cell metabolism in a glutamine-dependent mode and promote antibody-productivity to cell-growth tradeoff.
Nguyen HB, Malinov NG, Puttagunta A, et al. · Metab Eng 2027
- SEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells.
Tat J, Lay FD, Stevens J, et al. · Metab Eng 2027
- A kinetically constrained dynamic flux balance analysis model predicts diverse CHO-cell culture process modes and conditions.
Reddy JV, Malinov N, Souvaliotis J, et al. · Metab Eng 2027
- Computationally inspired glycoengineering to maximise mAb β4-galactosylation.
Gomez Aquino I, Ghahremanzamaneh M, Tsopanoglou A, et al. · Metab Eng 2027
Also in development for Herpes Zoster
- Active Comparator vaccinePhase 36 trials
Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster
- su vaccineRZVPhase 32 trials
GSK · Herpes Zoster, Respiratory Syncytial Virus (RSV)
- SCTV04CRecombinant Herpes Zoster Vaccine -DosePhase 21 trial
Sinocelltech Ltd. · Herpes Zoster
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.